Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4)

No abstract is available for this paper.

• Publication year

  2011

• Venue

  MedChemComm

• Publication date

  2011-06-08

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1039/C0MD00238K
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis

  2010cited by this paper
• Genome‐wide analysis of allelic imbalances reveals 4q deletions as a poor prognostic factor and MDM4 amplification at 1q32.1 in hepatoblastoma

  2010cited by this paper
• The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias

  2010cited by this paper
• Differential binding of p53 and nutlin to MDM2 and MDMX: Computational studies

  2010cited by this paper
• Widespread Overexpression of Epitope-Tagged Mdm4 Does Not Accelerate Tumor Formation In Vivo

  2010cited by this paper
• Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system.

  2010cited by this paper
• Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.

  2010cited by this paper
• The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers

  2010cited by this paper
• Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery

  2010cited by this paper
• A left-handed solution to peptide inhibition of the p53-MDM2 interaction.

  2010cited by this paper
• Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics

  2010cited by this paper
• MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild‐type CLL with a poor cytotoxic response to Nutlin‐3

  2010cited by this paper
• Pharmacological rescue of p53 in cancer therapy: widening the sensitive tumor spectrum by targeting MDMX.

  2010cited by this paper
• Puzzling over MDM4-p53 network.

  2010cited by this paper
• A stapled p53 helix overcomes HDMX-mediated suppression of p53.

  2010cited by this paper
• MDM4 binds ligands via a mechanism in which disordered regions become structured

  2010cited by this paper
• Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4.

  2010cited by this paper
• Turning the RING Domain Protein MdmX into an Active Ubiquitin-Protein Ligase*

  2010cited by this paper
• Bing De Ling, a Chinese herbal formula, inhibits cancer cells growth via p53.

  2010cited by this paper
• Small-molecule inhibitors of MDM2 as new anticancer therapeutics.

  2010cited by this paper
• Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway.

  2010cited by this paper
• Identification and Characterization of the First Small Molecule Inhibitor of MDMX*

  2010cited by this paper
• MDM4 (MDMX) localizes at the mitochondria and facilitates the p53‐mediated intrinsic‐apoptotic pathway

  2009cited by this paper
• RING domain E3 ubiquitin ligases.

  2009cited by this paper
• Knowledge-based virtual screening: application to the MDM4/p53 protein-protein interaction.

  2009cited by this paper
• Emerging roles of E2Fs in cancer: an exit from cell cycle control

  2009cited by this paper
• In Silico Improvement of beta3-peptide inhibitors of p53 x hDM2 and p53 x hDMX.

  2009cited by this paper
• Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.

  2009cited by this paper
• N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53.

  2009cited by this paper
• Apamin as a template for structure-based rational design of potent peptide activators of p53.

  2009cited by this paper
• High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx

  2009cited by this paper
• Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes*

  2009cited by this paper
• Targeting the conformational transitions of MDM2 and MDMX: Insights into key residues affecting p53 recognition

  2009cited by this paper
• Susceptibility of p53 Unstructured N Terminus to 20 S Proteasomal Degradation Programs the Stress Response*♦

  2009cited by this paper
• Beta-peptides with improved affinity for hDM2 and hDMX.

  2009cited by this paper
• Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX

  2009cited by this paper
• Mitochondrial MDM4 (MDMX): An unpredicted role in the p53-mediated intrinsic apoptotic pathway

  2009cited by this paper
• Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry?

  2009cited by this paper
• MDM2/MDMX inhibitor peptide: WO2008106507

  2009cited by this paper
• Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

  2008cited by this paper
• Targeting the Conformational Transitions of MDM2 and MDMX: Insights into Dissimilarities and Similarities of p53 Recognition

  2008cited by this paper
• Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans

  2008cited by this paper
• Mdm2 and Mdm4 Loss Regulates Distinct p53 Activities

  2008cited by this paper
• Expression of p14ARF, MDM2, and MDM4 in human retinoblastoma.

  2008cited by this paper
• Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties

  2008cited by this paper
• Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain

  2008cited by this paper
• High-Resolution Array-Based Comparative Genomic Hybridization of Bladder Cancers Identifies Mouse Double Minute 4 (MDM4) as an Amplification Target Exclusive of MDM2 and TP53

  2008cited by this paper
• Structure of human MDM4 N-terminal domain bound to a single-domain antibody.

  2008cited by this paper
• Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer

  2008cited by this paper
• Gene expression profiling of metastatic brain cancer.

  2007cited by this paper
• An essential function of the extreme C‐terminus of MDM2 can be provided by MDMX

  2007cited by this paper
• The Mdm2 RING domain C‐terminus is required for supramolecular assembly and ubiquitin ligase activity

  2007cited by this paper
• Molecular Basis for the Inhibition of p53 by Mdmx

  2007cited by this paper
• Etiology‐dependent molecular mechanisms in human hepatocarcinogenesis

  2007cited by this paper
• Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.

  2007cited by this paper
• RB1 and TP53 pathways in radiation-induced sarcomas

  2007cited by this paper
• High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.

  2007cited by this paper
• p53 in health and disease

  2007cited by this paper
• Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models.

  2007cited by this paper
• MDMX: from bench to bedside

  2007cited by this paper
• Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide

  2007cited by this paper
• Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.

  2006cited by this paper
• Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo

  2006cited by this paper
• Solution structure of the C4 zinc finger domain of HDM2

  2006cited by this paper
• Mouse bites dogma: how mouse models are changing our views of how P53 is regulated in vivo

  2006cited by this paper
• Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.

  2006cited by this paper
• Proteomimetic libraries: design, synthesis, and evaluation of p53-MDM2 interaction inhibitors.

  2006cited by this paper
• Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.

  2006cited by this paper
• Regulating the p53 pathway: in vitro hypotheses, in vivo veritas

  2006cited by this paper
• Cancer-Associated Mutations in the MDM2 Zinc Finger Domain Disrupt Ribosomal Protein Interaction and Attenuate MDM2-Induced p53 Degradation

  2006cited by this paper
• Epithelial-Restricted Gene Profile of Primary Cultures from Human Prostate Tumors: A Molecular Approach to Predict Clinical Behavior of Prostate Cancer

  2006cited by this paper
• Inactivation of the p53 pathway in retinoblastoma

  2006cited by this paper
• Real-time quantitative PCR analysis of gene dosages reveals gene amplification in low-grade oligodendrogliomas.

  2005cited by this paper
• Mdmx as an essential regulator of p53 activity.

  2005cited by this paper
• Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.

  2005cited by this paper
• Significance of HDMX‐S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis

  2005cited by this paper
• Real-Time Quantitative PCR Analysis of Regions Involved in Gene Amplification Reveals Gene Overdose in Low-Grade Astrocytic Gliomas

  2005cited by this paper
• Amplification of Mdmx (or Mdm4) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity

  2004cited by this paper
• MdmX Represses E2F1 Transactivation

  2004cited by this paper
• Nucleotide binding by the Mdm2 RING domain facilitates Arf-independent Mdm2 nucleolar localization.

  2003cited by this paper
• The E2F‐1 transcription factor is negatively regulated by its interaction with the MDMX protein

  2003cited by this paper
• Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.

  2003cited by this paper
• DNA Damage-induced MDMX Degradation Is Mediated by MDM2*

  2003cited by this paper
• HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53

  2003cited by this paper
• Mdm4 (Mdmx) Regulates p53-Induced Growth Arrest and Neuronal Cell Death during Early Embryonic Mouse Development

  2002cited by this paper
• MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts

  2002cited by this paper
• Mutual Dependence of MDM2 and MDMX in Their Functional Inactivation of p53*

  2002cited by this paper
• mdmx is a negative regulator of p53 activity in vivo.

  2002cited by this paper
• Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms

  2001cited by this paper
• Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53

  2001cited by this paper
• Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53.

  2001cited by this paper
• MdmX Protects p53 from Mdm2-Mediated Degradation

  2000cited by this paper
• Surfing the p53 network

  2000cited by this paper
• Comparative study of the p53-mdm2 and p53-MDMX interfaces

  1999cited by this paper
• Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.

  1999cited by this paper
• The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell‐cycle‐inhibitory function induces tumorigenesis

  1998cited by this paper
• Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

  1997cited by this paper
• MDMX: a novel p53‐binding protein with some functional properties of MDM2.

  1996cited by this paper
• Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

  1996cited by this paper
• Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

  1995cited by this paper

• Mechanistic Role of the Mdm2/MdmX Lid Domain in Regulating Their Interactions with p53

  2025cites this paper
• Synthesis, XRD, HAS, in silico molecular docking studies and biological assessment of novel Schiff base compounds as anti-cancer and antimicrobial agents

  2020cites this paper
• Computational modeling of cyclic peptide inhibitor–MDM2/MDMX binding through global docking and Gaussian accelerated molecular dynamics simulations

  2020cites this paper
• Focused Library Generator: case of Mdmx inhibitors

  2019cites this paper
• Synthesis, characterization, and antiproliferative and apoptosis inducing effects of novel s-triazine derivatives

  2018cites this paper
• A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.

  2017cites this paper
• Motif mediated protein-protein interactions as drug targets

  2016cites this paper
• Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review

  2016cites this paper
• Medicinal Chemistry Strategies to Disrupt the p53–MDM2/MDMX Interaction

  2016cites this paper
• Development of cell‐penetrating peptide‐based drug leads to inhibit MDMX:p53 and MDM2:p53 interactions

  2016cites this paper
• Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.

  2015cites this paper
• 14 P 53 Network in Ovarian Cancer

  2014cites this paper
• Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.

  2014cites this paper
• Efficient reactivation of p53 in cancer cells by a dual MdmX/Mdm2 inhibitor.

  2014cites this paper
• Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

  2013influential citation
• P53 Network in Ovarian Cancer

  2012cites this paper
• Small molecules as pro-apoptotic anticancer agents.

  2012cites this paper